Radiopharm Theranostics Ltd ADR RADX

$16.19 +10.59 (189.11%)

Valuation

Market cap
—
Revenue TTM
—
Net income TTM
—
PE ratio
—
Forward PE
—
Profit margin
—
Debt to equity
—

Trading

Volume
10,245
Avg volume
—
Day's range
$5.60 – $16.19
Shares out
—
Stochastic %K
—
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER...

Show more

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Industry
Biotechnology
Sector
Healthcare
Phone
61 3 9824 5254
Website
https://www.radiopharmtheranostics.com
Address
62 Lygon Street, Level 3, Carlton, Australia

Latest news

No headlines yet.

Stocktwits

Lalalilala Oct 2, 3:58 PM 1 replies
Ontherag Oct 1, 5:51 PM
$RADX oral presentation at sno is great, hopefully they present the full dataset and have a partnership lined up. This will barcode for awhile
2 replies
Lalalilala Oct 1, 12:22 PM
$RADX Those bastards are going to make us wait until the very last minute!
2 replies
Lalalilala Oct 1, 4:27 AM
$RADX 😐
0 replies
Lalalilala Sep 30, 5:35 PM
$RADX Let's not forget: promises are only binding on those who believe them, but conviction and vision are what make real investments. Despite the surrounding noise (even I'm still a little angry) and a "summer" correction on the RAD101 that tested our nerves, let's remain clear-headed. Last year, between September and December 2025, I executed a trade right here with record gains (almost all wiped out virtually now), but I fully intend to repeat this scenario in Q4 2026 or Q1 2027 ( buyback). Admittedly, this trade requires more time and is more complex, but the fundamentals and solid partners are in place. The tide always turns for those who know how to hold their ground. Ready for the FDA's verdict! "I am trying to convince myself that this "bad" strategy of a very aggressive offer for shareholders already positioned was in any case essential in order to be able to negotiate and also to wait to take us to the beginning of this phase 3. I believe that the worst is behind us tonight.
1 replies
Ontherag Sep 30, 3:00 PM
$RADX company sucks
1 replies
Lalalilala Sep 30, 1:41 PM
$RADX I hope this is the last blow we'll take and that things will get better starting tomorrow....
1 replies
History101 Sep 29, 7:27 PM
$RADX added
0 replies